Aktienanalyse zu Profusa Inc (PFSA)PFSAProfusa Inc

Profusa, Inc. is a digital health company developing tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its injectable and biosensors and its intelligent data platform, the Company is focused on providing people with a personalized biochemical signature. Its offering in the European Union, the Lumee Oxygen Platform, monitors tissue oxygen levels and is intended for applications such as peripheral artery disease, chronic wounds (including diabetic ulcers and pressure sores), and reconstructive surgery. Its research and development efforts are primarily focused on the Lumee Glucose Platform, a continuous glucose monitor (CGM) consisting of a biocompatible gel injected under the skin that monitors interstitial glucose levels for several months from a single injection. Its Data Discovery Platform, built on NVIDIA AI, transforms the continuous stream of biochemical sensor data into personalized clinical insights. It operates in the Healthcare sector.

Profusa Inc (PFSA) is not a good buy right now due to significant financial losses and poor technical indicators. The stock is currently priced at $0.84, with a year-to-date change of -99.89%, indicating severe underperformance. The RSI is at 28.434, suggesting it is oversold, but this does not guarantee a price rebound. Additionally, the company reported a net loss of $8.8 million in Q2 2026, which raises concerns about its financial health. The main risk is the company's current liabilities of $28.2 million against only $719,000 in cash, indicating a precarious financial position.